Ignite Creation Date:
2024-05-05 @ 7:19 PM
Last Modification Date:
2024-10-26 @ 9:47 AM
Study NCT ID:
NCT00646425
Status:
TERMINATED
Last Update Posted:
2010-08-19
First Post:
2008-03-26
Brief Title:
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable Noninfectious Uveitis
Sponsor:
Cerimon Pharmaceuticals
Organization:
Cerimon Pharmaceuticals
Study Overview
Official Title:
Randomized Double-Masked Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications
Status:
TERMINATED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BSX-003
Brief Summary:
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None